Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder

Next Previous
Trial Profile

The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Quetiapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 18 Oct 2006 The expected completion date for this trial is now .
  • 27 Mar 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top